

Yuichi Hikichi, et al.  
USSN: 10/500,216  
Pages 5 of 9

RECEIVED  
CENTRAL FAX CENTER  
AUG 28 2006

### REMARKS

The Applicants appreciate the Examiner's thorough examination of the subject application. Applicants request reconsideration of the subject application based on the instant amendments to the claims and drawings and the following remarks.

Claims 12, 19 and 23-27 are pending in the application. Claims 12, 23 and 25 are amended. Support for the amended claims can be found throughout the specification. No new matter has been introduced by the instant amendments. Applicants reserve the right to pursue the subject matter cancelled by this or a prior action in this or a subsequent continuation application.

Claims 12, 19 and 23-27 stand rejected under 35 U.S.C. §103(a) as obvious over the Jenuwein et al (US PAT 6555329 B2 in view of Jenuwein et al (US PAT 6689583)

Claims 24-25 and 27 stand rejected under 35 U.S.C. §103(a) as obvious over Kouzarides et al. (WO 02/090578) in view of Jenuwein et al (US PAT 6689583)

### Rejection under 35 USC § 103(a)

Claims 12, 19 and 23, 25-26 stand rejected under 35 U.S.C. 103(a) as obvious over Jenuwein et al (US PAT 6555329 B2, hereinafter D1) in view of Jenuwein et al (US PAT 6689583, hereinafter D2) The office action stated as follows:

Jenuwein et al (US PAT 6555329B2) teaches methods of screening modulators of histone methyl transferase comprising amino acid sequence of SEQ ID NO: 7(sic)(56% identical to SEQ ID NO: 1), and suggested them as therapeutic agent for cancer and apoptosis inducer.

Jenuwein et al (US PAT 6689583) teach a histone methyltransferase protein of SEQ ID NO: 4 which has 100% sequence identity with the SEQ ID NO: 1 of the present application. Jenuwein et al (US PAT 6689583) used radio-labeled methyl group of S-adenosyl-L-methionine to measure the said methyl group transfer to N-terminal lysine residue (Lysine 9 of H3 N-terminus) of histone polypeptide (page 6 lines 30-60).

Yuichi Hikichi, et al.  
USSN: 10/500,216  
Pages 6 of 9

As such it would have been obvious to one of ordinary skill in the art to use Jenuwein et al's (US PAT 6689583) histone methyltransferase protein of SEQ ID NO: 4 (which has 100 % sequence identity with the SEQ ID NO: 1 of the present application) and Jenuwein et al's (US PAT 6689583) assay method comprising radio-labeled methyl group of S-adenosyl-L-methionine in measuring the methyl transfer to N-terminal lysine residue (lysine 9 of H3 N-terminus) of histone methyltransferase polypeptide and use the said histone methyl transferase polypeptide and assay method comprising radio-labeled methyl group of S-adenosyl-L-methionine to measure the methyl transfer to N-terminal lysine residue to screen modulators of histone methyl transferase as therapeutic agent for cancer and apoptosis inducer as taught by Jenuwein et al. (US PAT 655329B2).

The rejection is respectfully traversed.

The amended claims 12 and 23 are specifically directed to methods of screening a preventive or therapeutic agent for breast cancer. The method comprises either measuring and comparing the radioactivities of histone H3, or a polypeptide having the N-terminal sequence of histone H3 by transfer of the methyl group or measuring and comparing methylated lysine residues, (i) in the case where a protein containing the amino acid sequence of SEQ ID NO: 1 or a salt thereof is reacted with (a) S-adenosyl-L-methionine wherein the methyl group is radio-labeled and (b) histone protein or a polypeptide having the N-terminal sequence of histone H3 and (ii) in the case where a protein containing the amino acid sequence of SEQ ID NO: 1 or a salt thereof is reacted with (a) S-adenosyl-L-methionine wherein the methyl group is radio-labeled and (b) histone protein or a polypeptide having the N-terminal sequence of histone H3 in the presence of a test compound.

The specification of the present application taught and specifically substantiated the methods of screening a preventive or therapeutic agent for breast cancer. For example, in EXAMPLE 1 of the present specification, it was substantiated that SUV39H1 is specifically expressed in the breast cancer tissue (Patient No.6: see TABLE 2). In EXAMPLE 2, it was substantiated that SUV39H1 is not only expressed specifically in the breast cancer tissue, but is engaged in cancer cell growth. On the other hand, neither D1 nor D2 disclosed that an HMTase gene is specifically expressed

Yuichi Hikichi, et al.  
USSN: 10/500,216  
Pages 7 of 9

in cancer tissue, especially breast cancer tissue. Nor was there a disclosure or suggestion that the HMTase gene is involved in breast cancer cell growth. Thus, it is apparent that the present inventors found and substantiated, for the first time, that SUV39H1 is specifically related to breast cancer.

As to claims 19 and 26 directed to method of screening an apoptosis inducer, HMTase (SEQ ID NO: 2) described in D1 only has 56% sequence identity with HMTase in D2 (SEQ ID NO: 4: identical to HMTase of the present invention). It is believed that the sequence homology is quite different between these proteins, to combine the teachings of D1 and D2 to arrive at the present screening method.

Further, there are critical differences between HMTase described in D1 and that in D2 as discussed below.

First, it was reported by Jenuwein that tissue distribution of HMTase in D1 was different from HMTase in D2 (Mol Cell Biol. 2000 Dec; 20(24): 9423-33; attached herewith). Suv39h2 (identical to HMTase in D1) is expressed specifically in testes, while Suv39h1 (identical to HMTase in D2) shows relatively broad expression (Fig. 5A). These data suggest that each of the proteins plays a different role in different cells or tissues.

Second, there is a structural difference between Suv39h2 (D1) and Suv39h1 (D2). Suv39h2 comprises a highly basic N-terminal extension with 82 amino acids, which is not present in Suv39h1. This difference was also mentioned in the paper (Fig. 1B). It is well accepted by a skilled person that a difference in a protein function depends upon a difference in secondary structure of the protein. Thus, one skilled in the art should recognize that it is hard to predict actual cellular function of Suv39h1 and Suv39h2 and to place Suv39h1 and Suv39h2 in the same class, while both proteins have HMTase activities.

Therefore, there is neither suggestion nor motivation for combining D1 with D2 in these references. It is not believed obvious for a skilled person to use modulators of HMTase obtainable by the assay method in D2 as apoptosis inducer as taught by D1.

Any rejection of a claim for obviousness over a combination of prior art references must establish that (1) the combination produces the claimed invention and

Yuichi Hikichi, et al.  
USSN: 10/500,216  
Pages 8 of 9

(2) the prior art combines a suggestion or motivation to combine the prior art references in such a way as to achieve the claimed invention (In re Vaek, 947 F.2d 488; 20 USPQ2d 1438-Fed.Cir.1991). In addition, the Examiner's prima facie case must include a finding that one of ordinary skill in the art at the time the invention was made would have reasonably expected the claimed invention to work (In re O'Farrell, 853 F.2d 894, 903-904; USPQ2d 1529, 1531-Fed. Cir. 1988). IN the present office action, the Examiner has not established a prima facie case of obviousness.

Thus, for at least these reasons, claims 12, 19 and 23, 25-26 are patentable over D1 and D2.

Claims 24-25 and 27 stand rejected under 35 U.S.C. 103(a) as obvious over Kouzarides et al. (WO 02/090578, hereinafter D3) in view of Jenuwein et al (US PAT 6689583, D2) The office action stated as follows:

Kouzarides et al. teaches methods of screening modulators of histone methyl transferase by measuring the methylated and unmethylated histone polypeptide reacted with s-adenosyl-L-methionine in presence of test compound using MALDI Mass spectrometry and suggested them as therapeutic agent for cancer and apoptosis induce.

The rejection is respectfully traversed.

The applicants disagree with the above contention. In D3, mass spectrometry was used for identifying a protein relating to methylation of histone (see, e.g., line 23 in page 48 to line 7 in page 49, line 28 in page 53 to line 14 in page 54 of D3). On the hand, in the present invention, mass spectrometry was used for screening modulators of HMTase (see, e.g., page 30, lines 2-12 of the specification) Thus, it is believed that a skilled person could not have been motivated to combine D2 and D3, to utilize the mass spectrometry for the screening method as disclosed in D2.


Thus, for at least these reasons, claims 24, 25 and 27 are patentable over D2 and D3.

Yuichi Hikichi, et al.  
USSN: 10/500,216  
Pages 9 of 9

In view of the foregoing, applicants respectfully request reconsideration, withdrawal of all grounds of rejection and objection, and allowance of claims 12, 19 and 23-27 in due course.

Respectfully submitted,

Date: August 28, 2006

  
\_\_\_\_\_  
Jun Umemuro  
Limited Recognition No. L0247  
David G. Conlin  
Registration No. 27,026  
EDWARDS ANGELL PALMER & DODGE LLP  
P.O. Box 55874  
Boston, Massachusetts 02205  
Tel. No. (617) 517-5564  
Customer No. 21,874

MOLECULAR AND CELLULAR BIOLOGY, Dec. 2000, p. 9423–9433  
 0770-7306/00/\$04.00+0  
 Copyright © 2000, American Society for Microbiology. All Rights Reserved.

Vol. 20, No. 24

## Isolation and Characterization of *Suv39h2*, a Second Histone H3 Methyltransferase Gene That Displays Testis-Specific Expression

DÓNAL O'CARROLL,<sup>1</sup> HARRY SCHERTMAN,<sup>2</sup> ANTOINE H. F. M. PIETERS,<sup>1</sup> SUSANNE O'RAVIL,<sup>1</sup>  
 ANDREW R. HAYNES,<sup>3</sup> GÖTZ LAIBLE,<sup>1†</sup> STEPHEN REA,<sup>1</sup> MANFRED SCHMID,<sup>1</sup> ANGELIKA LEBERSORGER,<sup>1</sup>  
 MARTIN JERRATSCH,<sup>2</sup> LYDIA SATTLER,<sup>4</sup> MARIE G. MATTI,<sup>5</sup> PAUL DENNY,<sup>3</sup> STEPHEN D. M. BROWN,<sup>3</sup>  
 DIETER SCHWEIZER,<sup>4</sup> AND THOMAS JENUWEIN<sup>1\*</sup>

Research Institute of Molecular Pathology at The Vienna Biocenter,<sup>1</sup> and Institute of Botany, University of Vienna,<sup>4</sup>  
 A-1030 Vienna, Austria; Institute of Human Biology, University of Kaiserslautern, D-67663 Kaiserslautern, Germany<sup>2</sup>;  
 Mouse Genome Centre and Mammalian Genetics Unit, Medical Research Council, Harwell, Oxon OX11 0RI,  
 United Kingdom<sup>3</sup>; and INSERM U106, Génétique Médicale et Développement, 13385 Marseille Cedex 5, France<sup>5</sup>

Received 26 September 2000/Accepted 28 September 2000

Higher-order chromatin has been implicated in epigenetic gene control and in the functional organization of chromosomes. We have recently discovered mouse (*Suv39h1*) and human (*SUV39H1*) histone H3 lysine 9-selective methyltransferases (*Suv39h* HMTases) and shown that they modulate chromatin dynamics in somatic cells. We describe here the isolation, chromosomal assignment, and characterization of a second murine gene, *Suv39h2*. Like *Suv39h1*, *Suv39h2* encodes an H3 HMTase that shares 59% identity with *Suv39h1* but which differs by the presence of a highly basic N terminus. Using fluorescent *in situ* hybridization and haplotype analysis, the *Suv39h2* locus was mapped to the subcentromeric region of mouse chromosome 2, whereas the *Suv39h1* locus resides at the tip of the mouse X chromosome. Notably, although both *Suv39h* loci display overlapping expression profiles during mouse embryogenesis, *Suv39h2* transcripts remain specifically expressed in adult testes. Immunolocalization of *Suv39h2* protein during spermatogenesis indicates enriched distribution at the heterochromatin from the leptotene to the round spermatid stage. Moreover, *Suv39h2* specifically accumulates with chromatin of the sex chromosomes (XY body) which undergo transcriptional silencing during the first meiotic prophase. These data are consistent with redundant enzymatic roles for *Suv39h1* and *Suv39h2* during mouse development and suggest an additional function of the *Suv39h2* HMTase in organizing meiotic heterochromatin that may even impart an epigenetic imprint to the male germ line.

In eukaryotes, control of gene expression and the functional organization of chromosomes depends on higher-order chromatin, which has been proposed to be nucleated by the covalent modification of histone amino termini (45). In addition to its role in somatic cells, dynamic transitions in the organization of higher-order chromatin are also important during meiosis (15). Although condensation and pairing of meiotic chromosomes is evolutionarily highly conserved, meiosis in male mammals is exceptional because the heteromorphic X and Y chromosomes undergo facultative heterochromatinization that is accompanied by transcriptional silencing (21). This selective inactivation of the sex chromosomes, which is cytologically defined by the appearance of the so-called XY body or sex vesicle (44), has been suggested to restrict promiscuous pairing or recombination between nonhomologous chromosomes, thereby reducing the risk for aneuploidy (21).

Despite the apparent resemblance of the XY body to the Barr body (9) in female somatic cells, it is currently unresolved whether similar mechanism(s) operate in inducing chromosome-specific heterochromatinization in meiotic and somatic cells. For example, although *Xist* RNA also localizes to the XY body (5), spermatogenesis is unaffected in *Xist*-deficient mice

(29). Moreover, only a few proteins that associate with the XY body have been described (12, 23, 26, 43) of which M31 (HIP1 $\beta$ ) represents the first bona fide heterochromatic component (32, 49). Because *M31* (HIP1 $\beta$ ) is a mammalian member of the *Su(var)* gene family, this result suggested a possible link between heterochromatin-induced gene repression in somatic tissues and transcriptional silencing of the sex chromosomes during male meiosis.

*Su(var)* genes were initially identified by genetic screens on centromeric position effects in *Drosophila melanogaster* (37) and *Schizosaccharomyces pombe* (3). Since *Su(var)* genes suppress position effect variegation (PEV), their gene products have been implicated in the organization of repressive chromatin domains. Indeed, characterized family members represent either chromosomal proteins or enzymes that can modify chromatin (47). Recently, we isolated mouse (*Suv39h1*) and human (*SUV39H1*) homologs (1) of the dominant *Drosophila* PEV modifier *Su(var)3-9* (46) and demonstrated that they encode histone methyltransferases which selectively methylate lysine 9 (Lys9) in the histone H3 N terminus (36). Immunolocalization of endogenous *Suv39h1* or *SUV39H1* proteins in mammalian cells indicated enriched distribution at heterochromatic foci during interphase and transient accumulation at centromeric positions during mitosis (2). In addition, *Suv39h1* or *SUV39H1* associate with M31 (HIP1 $\beta$ ), indicating the existence of a mammalian SU(VAR) protein complex (1). Moreover, deregulated *SUV39H1* can induce ectopic heterochromatin and redistribute endogenous M31 (HIP1 $\beta$ ) (30). Together, our data defined *Suv39h1* or *SUV39H1* as novel

\* Corresponding author. Mailing address: Research Institute of Molecular Pathology at the Vienna Biocenter, Dr. Bohrergasse 7, A-1030 Vienna, Austria. Phone: (43/1) 797-30-474. Fax: (43/1) 798-7153. E-mail: jenuwein@imp.univie.ac.at.

† Present address: Dairy Science Group, AgResearch, Hamilton, New Zealand.

heterochromatin-associated HMTases that are intrinsically involved in the structural organization of mammalian higher-order chromatin in somatic cells.

We describe here the isolation and characterization of a second murine *Suv39h* gene, *Suv39h2*. Over the entire length of the 477-amino-acid protein, Suv39h2 shares 59% identity with Suv39h1 and also displays an H3-Lys9-selective HMTase activity. However, Suv39h2 differs from Suv39h1 by the presence of a very basic, histone H1-like N terminus. Moreover, whereas both murine *Suv39h* loci show overlapping expression profiles during embryogenesis, *Suv39h2* transcripts are restricted to adult testes. Immunolocalization of endogenous Suv39h2 protein reveals enriched distributions at heterochromatin during the first meiotic prophase and in the early stages of spermiogenesis. During mid-pachytene, Suv39h2 specifically accumulates with chromatin of the silenced sex chromosomes present in the XY body. These data are consistent with redundant gene functions for both *Suv39h* loci during mouse development but, in addition, suggest a role for the Suv39h2 HMTase in regulating higher-order chromatin dynamics during male meiosis.

#### MATERIALS AND METHODS

**Molecular cloning of murine *Suv39h2*.** A 210-bp EST DNA probe (encoding amino acids 219 to 289 of Suv39h2, see Fig. 1) was PCR amplified from murine B cell-specific (J5581, and S194) cDNA libraries and screened against a day 11.5 mouse embryonic  $\lambda$ gt11 cDNA library (Clontech) and a  $\lambda$ 129/Sv genomic library (Stratagene), resulting in the isolation of six cDNA and three genomic clones. The longest cDNA (1 kb;  $\lambda$ 1-Suv39h2) and genomic (14-kb) isolates were sequenced by primer walking on an automated sequencer (Applied Biosystems). Sequence analysis indicated that the  $\lambda$ 1-Suv39h2 cDNA encoded amino acids 132 to 477 and that the genomic sequence comprised exons 1 to 3, as predicted by GENIE-Finder. Missing 5' sequences of the Suv39h2 cDNA were extended by nested rapid amplification of cDNA ends (RACE) (Marathon cDNA Amplification Kit; Clontech) from the J5581 and S194 cDNA libraries using the exon 3 specific primers 5'-GCCCTCCAAAGTCAACAGTG and 5'-GTGTTGAGGTAATCTTCCATC. The RACE amplifications identified exon 2 (amino acids 83 to 131). From 1, including the starting ATG, was deduced from an EST (accession no. AA939164) which correctly spliced into exon 2 and whose sequence information was confirmed by comparison with genomic sequences.

**Chromosomal assignment and fine mapping of the *Suv39h1* and *Suv39h2* loci.** To obtain genomic *Suv39h1* sequences, we hybridized a *Suv39h1*-specific DNA probe encoding amino acids 19 to 223 of Suv39h1 (1) against a  $\lambda$ 129/Sv genomic library (Stratagene). Among several isolates, a 13-kb partial genomic *Suv39h1* fragment comprising exons 1 to 3 was sequenced by primer walking. Both *Suv39h1* and *Suv39h2* genomic sequences were subcloned into plasmid (see Fig. 2, top) and used for fluorescence in situ hybridization (FISH) analysis on Robertsonian mouse chromosomes as described previously (28). Fine mapping by single-stranded conformation polymorphism (SSCP) was performed with a 170-bp exon 3, intron 3-specific DNA probe for *Suv39h1* (primers 5'-CACTAATGATGGCCGAGG and 5'-GCAGAGAGGTTGAGGTACAG) and with the 210 bp exon 3-specific EST-Suv39h2 probe (primers 5'-GGGGATGATATTCGTTGAAAAC and 5'-GGTTGGATTTAATTTGTTGCTTC). The SSCP analysis and calculation of genetic distances was as recently reported (28).

**RNA isolation and blot analysis.** RNA isolation and analysis was done as described previously (1). Membranes were sequentially hybridized under stringent conditions (41) with a 1.6-kb *EcoRI* cDNA fragment comprising nearly full-length *Suv39h1* (1) or with a 980-bp cDNA PCR amplicon which codes for amino acids 143 to 477 of *Suv39h2*. To control for the quality of the RNA preparations, blots were rehybridized with a DNA probe that is specific for *Gad6h* sequences (17).

**In situ hybridization for *Suv39h1* and *Suv39h2* expression.** To obtain *Suv39h1*- and *Suv39h2*-specific riboprobes, PCR-amplified *Sall/BamHI* DNA fragments were subcloned into the polylinker of pGEM-3Zf (Promega). Similar to an internal 395-bp DNA fragment encoding amino acids 113 to 237 of Suv39h1 (1), a 325-bp internal DNA fragment encoding amino acids 186 to 290 of Suv39h2 was used. Within this region, *Suv39h1* and *Suv39h2* nucleotide sequences are only ~53% identical and do not cross-hybridize. In situ RNA probes were internally labeled with DIG-UTP (Boehringer Mannheim) by transcription with SP6 (antisense probes of *EcoRI* linearized plasmid) or T7 RNA polymerase (sense probes of *BamHI* linearized plasmid).

**In situ hybridizations of whole-mount embryos or of 5- $\mu$ m sections of paraffin-embedded testes** were performed at 65 to 70°C overnight, washed under high stringency, and processed for detection after incubation with a DIG alkaline phosphatase-conjugated antibody and BM purple as the chromogenic substrate (Boehringer Mannheim).

**Generation and purification of rabbit polyclonal  $\alpha$ -Suv39h2-specific antibodies.** *Suv39h2* coding sequences comprising amino acids 157 to 477 were converted into a *BamHI*/*EcoRI* DNA fragment by PCR amplification and combined in-frame with N-terminal glutathione S-transferase (GST) in the bacterial expression vector pGEX-2f (Pharmacia). Purification of recombinant protein and immunization of rabbits with the GST-Suv39h2 antigen was done as described elsewhere (1). An immunoglobulin G fraction was prepared from the crude serum of rabbit 2218, batch preadsorbed against GST-Suv39h1 glutathione-Sepharose beads (1), and  $\alpha$ -Suv39h2 antibodies were affinity purified over a glutathione-Sepharose (Pharmacia) column that had been loaded with GST-Suv39h2. After elution with 100 mM glycine (pH 2.5), antibodies were neutralized with a 1/10 volume of 2 M HEPES (pH 7.9). These affinity-purified  $\alpha$ -Suv39h2 antibodies (concentration, ~0.5 mg/ml) were used at 1:250 or 1:500 dilutions for protein blot analysis or at 1:10 to 1:20 dilutions for indirect immunofluorescence.

**Epitope-tagged Suv39h2 protein in HeLa cells.** To generate a (myc)<sub>3</sub>-tagged Suv39h2 protein that would resemble the shorter Suv39h1 or Suv39h1 gene products, the portion of the *Suv39h2* cDNA comprising amino acids 83 to 477 was converted into a *NcoI/XhoI* DNA fragment by PCR amplification and transferred into a *NcoI/XhoI*-digested pKWT-(myc)<sub>3</sub>-1/SUV39h1 derivative which contains a unique in-frame *NcoI* cloning site immediately following the N-terminal tag (1). The (myc)<sub>3</sub>-Suv2(83-477) construct was confirmed by sequencing and "stably" cotransfected into HeLa cells as described earlier (1). One clone (HeLa-S2/5) with significant overexpression of the ectopic protein in ~65% of clonal cells was characterized further and, together with HeLa-h155 cells which overexpress (myc)<sub>3</sub>-SUV1(3-412) (30), used to analyze specificity of the  $\alpha$ -Suv39h2 antibodies.

**Isolation of PMEFs.** Primary mouse fibroblasts (PMEFs) were derived from day E12.5 C57BL/6J295v1 fetuses after removing the head and inner organs. Trunk tissues were partially homogenized in 5 ml of medium by repeated passage through a 20 gauge hypodermic needle, resuspended onto a 10-cm-diameter dish, and cultivated in high-glucose Dulbecco modified Eagle medium supplemented with 15% fetal calf serum, 2 mM glutamine, 1% nonessential amino acids, 0.1 mM  $\beta$ -mercaptoethanol, 1% penicillin-streptomycin (all Gibco-BRL). This primary culture was trypsinized after 3 days, and the floating single cell suspension was expanded into passage 1, which already contained a highly enriched population of PMEFs.

**Nuclear extracts and protein blot analysis.** Isolation of nuclei from mouse testes was performed according to described protocols (11, 32). Approximately 30  $\mu$ g of nuclear extracts from testes, the HeLa cell clones, or from PMEFs were analyzed on protein blots with  $\alpha$ -myc,  $\alpha$ -M31 (11P1B) (19),  $\alpha$ -Suv39h1, and  $\alpha$ -Suv39h2 antibodies as reported elsewhere (1).

**HMTase assays with recombinant Suv39h2.** Methyltransferase assays with free histones (Boehringer Mannheim) or histone H3, CENP-A, and macroH2A N-terminal peptides and the recombinant GST-Suv2(157-477) product were done as recently described (36).


**Immunofluorescence analysis of testes sections.** Testes were surgically removed from adult C57BL/6J295v1 mice, embedded in O.C.T. 4851 (Tissue-Tek), and frozen in liquid nitrogen using precooled isopentane. Then, 10  $\mu$ m sections were fixed in 2% paraformaldehyde in phosphate buffered saline (PBS; pH 7.4) for 10 min on ice, washed in cold PBS, and treated with 0.1% sodium citrate buffer (pH 6.0) containing 0.1% Triton X-100 for 5 min on ice. Subsequently, the sections were washed and blocked with PBS-2.5% bovine serum albumin (BSA)-0.1% Tween 20-10% goat serum for 30 min at room temperature.

**For indirect immunofluorescence of M31 (11P1B) and Sep3 epitopes,** sections were simultaneously incubated with rat monoclonal  $\alpha$ -M31 antibodies (49) and mouse monoclonal  $\alpha$ -Sep3 antibodies (22) overnight at 4°C. After several washes (PBS, 0.25% BSA, 0.1% Tween 20), samples were incubated for 1 h at room temperature with secondary CY3-conjugated goat anti-rat and CY5-conjugated goat anti-mouse antibodies (both from Dianova). After three final washes with PBS containing 0.1% Tween 20, sections were mounted in Vectashield antifade solution (Vector Laboratories) containing 4',6'-diamidino-2-phenylindole (DAPI).

**For double labeling of Suv39h2 and Sep3 epitopes,** sections were incubated with rabbit polyclonal  $\alpha$ -Suv39h2 antibodies and mouse monoclonal  $\alpha$ -Sep3 antibodies. Suv39h2 staining was visualized by immunoprecipitation, using biotinylated goat anti-rabbit antibodies, Alexa488-conjugated avidin, biotinylated goat anti-avidin antibodies, and Alexa488-conjugated avidin (Vector Laboratories and Molecular Probes). Sep3 epitopes were visualized by secondary Alexa488-conjugated goat anti-mouse antibodies (Molecular Probes). Processed samples were evaluated using a Zeiss Axiovert epifluorescence microscope. Digital black-and-white images were recorded with a cooled charge-coupled device camera (Princeton Instruments), merged to RGB images using the MetaMorph Imaging System (Universal Imaging Corporation), and processed in Adobe Photoshop 5.1.

**Immunofluorescence analysis of testis suspension cells.** Testes were minced with scalpel blades in cold minimal essential medium (Gibco) containing protease inhibitors (Roche Biochemicals). Structurally preserved suspension cells were prepared by cross-linking fixation as described elsewhere (35). Testis suspension cells were mixed with equal volumes of PBS-buffered (pH 7.2) 3.7% formaldehyde-0.1 M sucrose, placed on adhesion glass slides, and allowed to dry down until they were coated by a thin layer of sucrose.

Vol. 20, 2000

TESTIS-SPECIFIC EXPRESSION OF *Suv39h2* 9425



9426 O'CARROLL ET AL.

MOL. CELL. BIOL.




FIG. 2. Genomic organization and chromosomal localization of the *Suv39h1* and *Suv39h2* loci. (Top) Organization of partial genomic clones comprising the 5' regions of murine *Suv39h1* and *Suv39h2*. Exons are shown by black boxes, and numbers indicate the starting amino acid positions of the respective exons. Delineated by the dashed lines are exon regions that encode the conserved chromo domain. Both loci are drawn to scale, and the respective *Suv39h1* and *Suv39h2* subclones (dashed lines above the loci) that were hybridized to metaphase spreads (below) are shown, as are the specific primer pairs (split arrows) used for the haplotype analysis (see Fig. 3). (Bottom) FISH analysis of *Suv39h1* and *Suv39h2* localization on metaphase chromosomes prepared from lymphocytes of WMP male mice. Chromosomes were counterstained and stained with propidium iodide. Arrowheads indicate symmetrical signals on the X chromosome for *Suv39h1* (left panel) and on the Rb(2;16) chromosome for *Suv39h2* (right panel). Based on the R banding, localization of *Suv39h1* is assigned to regions A1 and A2 of chromosome X and that of *Suv39h2* to region A of chromosome 2.

probe was PCR amplified from murine cDNAs and screened against a mouse embryonic day 11.5 (E11.5) cDNA library (see Materials and Methods). Of six positive isolates, the longest insert was subcloned and sequenced, revealing an open reading frame (ORF) which comprises the chromo and the C-terminal SET domain. RACE amplifications with cDNA templates from the murine B-cell-specific cell lines J5581 and S194 extended the missing 5' end; however, they did not detect a starting ATG.

To obtain more sequence information, a partial *Suv39h2* genomic clone of approximately 14 kb was isolated (see Materials and Methods). In addition, we also identified a partial genomic clone of approximately 13 kb for the mouse *Suv39h1* locus. Overall, the genomic organization, including the exon-intron structure and the presence of a predicted CpG-island across the first exon, is very similar for both loci (see Fig. 2 and below). Comparison of the available genomic, cDNA, and EST sequences for the *Suv39h1*-related gene allowed the definition of exon 1 (see Materials and Methods) that contains a consensus ATG preceded by in-frame stop codons and which can correctly splice into exon 2. In analogy to *Suv39h1*, we designated this novel gene *Suv39h2* [for *Su(var)3-9* homolog 2]. The nucleotide sequence (~1.5 kb) and conceptual reading frame (477 amino acids) of the composite coding *Suv39h2* cDNA are shown in Fig. 1A.

**Sequence conservation of Suv39h2 within the SU(VAR)3-9 protein family.** Over the length of the 477-amino-acid protein, *Suv39h2* is 59% identical to *Suv39h1* (412 amino acids) (1). Cross-species comparison of *Suv39h1* or *Suv39h2* with other representative members of the SU(VAR)3-9 protein family, such as *Drosophila* SU(VAR)3-9 (46), *S. pombe* CLR4 (25),

and a putative ORF in *Caenorhabditis elegans* (C15H11.5; accession no. Z81035) indicate very similar sequence identities and phylogenetic relationships (Fig. 1B).

Interestingly, however, *Suv39h2* contains a highly basic (20.7%) N-terminal extension of 82 amino acids that is not present in *Suv39h1*, although a very basic, yet distinct N terminus is also found in the C15H11.5 ORF. In addition to its resemblance to arginine-rich protamines, the *Suv39h2* N terminus shows moderate sequence identity (23.2%) with the C-terminal portion of the linker histone H1 that is not restricted to basic residues (Fig. 1C). With the exception of this extended N terminus, *Suv39h2* maintains all other conserved domains outlined previously for *Suv39h1* (1). For example, both proteins display highest identity in the 130-amino-acid SET domain core (75.2%) and in the conspicuous C-terminal tail (69.6%) with its three conserved cysteine residues. The 60-amino-acid chromo domain (62.7%), the SET-associated cysteine-rich region (54.9%), and the SU(VAR)3-9-specific N-terminal region (45.0%) are also highly identical. Like *Suv39h1*, *Suv39h2* is also significantly shorter than the 635-amino-acid fly protein (46).

**Chromosomal assignment of the murine *Suv39h1* and *Suv39h2* loci.** To investigate the chromosomal assignment of the two *Suv39h* loci, metaphase spreads prepared from stimulated lymphocytes of WMP mice, which are homozygous for metacentric Robertsonian (Rb) translocations in all autosomes except chromosome 19, were analyzed by FISH with genomic *Suv39h1* and *Suv39h2* DNA probes (Fig. 2, top, and Materials and Methods). The genomic *Suv39h1* probe indicated a symmetrical, two-dotted signal at the tip of the mouse X chromosome, a localization consistent with the previous assignment of




FIG. 3. Linkage mapping of *Suv39h1* and *Suv39h2* on mouse chromosomes X and 2. (Top) Haplotype analysis. The segregation of C57BL/6 or *M. spretus* parental alleles for *Suv39h1* (left panel), *Suv39h2* (right panel), and for the respective flanking microsatellite markers that are specific for chromosome X or chromosome 2 are shown. Each backcross progeny has inherited the indicated allele from the F<sub>1</sub> female parent. A white box indicates an *M. spretus* allele, and a black box indicates a C57BL/6 allele. Gray boxes represent markers that have not been scored. Numerals inside boxes reflect the number of selected recombinant progeny for which typings are missing in the FUCB database. The numbers above each column indicate the number of progeny inheriting each type of chromosome. The calculation of genetic distances and standard error, correcting for recombinants not typed, was done as described previously (28). (Bottom) Consensus maps for *Suv39h1* and *Suv39h2* loci. Since genetic distances are calculated from multiple crosses, they reflect the relative rather than the precise order of markers. All distances (in centimorgans) are according to MGI chromosome committee maps. The position of the corresponding *SUV39H1* locus (Xp11.2) on the human X chromosome (20) is also indicated.

a *SUV39H1* homologous sequence (MG-44) to the Xp11.2 region on the human X chromosome (20). In contrast, the genomic *Suv39h2* probe specifically hybridized with the A region of mouse chromosome 2 present in the Rb(2;16) translocation (Fig. 2, bottom).

The chromosomal position of the two murine *Suv39h* loci was further defined by haplotype analysis of recombinant progeny (*Mus spretus* × C57BL/6) from the European collaborative interspecific backcross (EUCB) (8, 38). Allelic variants were identified on a series of PCR-amplified DNA fragments by SSCP (see Materials and Methods). SSCP polymorphisms were detected with an exon 3-intron 3 primer pair for *Suv39h1* and with an exon 3-specific primer pair for *Suv39h2* (see Fig. 3, top). Each of these specific primer pairs was scored through a random panel of FUCB backcross mice, indicating linkage of *Suv39h1* to mouse chromosome X markers and of *Suv39h2* to mouse chromosome 2 markers (data not shown). Haplotype analysis localized *Suv39h1* to map position 1.8 cM of the mouse chromosome X, in an interval that also harbors the mouse mutations *lutealoid* (*ld*) (13) and *scurfy* (*Sf*) (39) (Fig. 3, left panel). In the parallel fine mapping of *Suv39h2*, haplotype analysis of a panel of 89 mice carrying recombinants in the

D2Mit11/D2Mit6 region localized *Suv39h2* to this interval. The *Suv39h2* locus lies  $0.7 \pm 0.4$  centimorgans (cM) distal of D2Mit355. Genetic distances taken from the Mouse Genome Database (<http://www.jax.org>) would indicate that *Suv39h2* resides at map position 2.5 cM of mouse chromosome 2 (Fig. 3, right panel).

**Temporal and spatial expression of *Suv39h1* and *Suv39h2* during mouse development.** To determine the expression and size of *Suv39h2* mRNAs, RNA blots containing total RNA from embryonic stem (ES) cells and mouse fetuses from various embryonic stages (days E10.5 to E17.5) and on postnatal days 1 to 4 (P1 to P4) were hybridized with a 980-bp cDNA probe comprising *Suv39h2* coding sequences (amino acids 143 to 477). Within this region, the *Suv39h2* cDNA is approximately 60% identical to the *Suv39h1* nucleotide sequence and does not cross-hybridize with *Suv39h1* transcripts (see Fig. 5A; also data not shown). This *Suv39h2*-specific cDNA probe recognized a prominent mRNA of approximately 2.7 kb in most RNA preparations of the analyzed stages (Fig. 4A, middle panel), whereas at day E10.5, smaller-sized (1.7-kb) transcripts were also detected. Abundant *Suv39h2*-specific transcripts are present in ES cells, in in vitro-differentiated embryoid bodies

9128 O'CARROLL ET AL.

MOL. CELL. BIOL.




FIG. 4. Temporal and spatial expression of *Suv39h1* and *Suv39h2* during mouse development. (A) RNA blot analysis to detect *Suv39h1* and *Suv39h2* transcripts in 15  $\mu$ g of total RNA prepared from undifferentiated CCE ES cells, EB derived after retinoic-acid-induced in vitro differentiation of CCE cells, and whole fetuses at various stages of embryonic (E10.5 to E17.5) and postnatal (P1 to P4) development. As a control for the quality of the RNA, the RNA blot was rehybridized with a probe that is specific for *Gapdh* sequences. (B) Whole-mount RNA in situ hybridizations of E8.5 and E9.5 mouse fetuses with *Suv39h1*- and *Suv39h2*-specific riboprobes. The arrow indicates the presence of *Suv39h1* transcripts in the allantois. As a control, fetuses were also hybridized with a *Suv39h2*-specific sense probe.

(EB), and appear to peak at ca. day E10.5. In contrast, *Suv39h2*-specific transcripts are substantially downregulated at day E17.5 and are nearly absent during postnatal development. A very similar dynamic expression profile was also observed for *Suv39h1*, except that the relative abundance of *Suv39h1* transcripts in ES cells and EB is reduced compared to *Suv39h2* transcripts (Fig. 4A, top panel). With a more sensitive RNase protection assay, however, *Suv39h1* has been shown to be expressed in ES cells (1).

To investigate the spatial expression profiles of *Suv39h2* and *Suv39h1*, we performed whole-mount in situ hybridizations with *Suv39h2*- and *Suv39h1*-specific riboprobes (see Materials and Methods) on day E8.5 and day E9.5 mouse fetuses. Whereas only residual staining is observed with a *Suv39h2* control sense probe, the *Suv39h2* antisense probe reveals a rather uniform expression throughout the entire fetus (Fig. 4B, middle panel). Similarly, the *Suv39h1* antisense probe detects

a broad distribution of transcripts, a finding consistent with the ubiquitous expression of *Suv39h1* in previous in situ hybridizations on sagittal sections of day E12.5 fetuses (1). In addition to embryonic tissues, the mesenchyme-derived allantois is also prominently stained by the *Suv39h1* antisense probe (Fig. 4B, arrow in left panel). Together with the RNA blot shown above, this comparative analysis indicates significant coexpression of *Suv39h1* and *Suv39h2* during mouse development.

*Suv39h2* transcripts are highly expressed in mouse testes. In contrast to embryonic expression profiles, the abundance of *Suv39h1* and *Suv39h2* transcripts greatly differs in adult tissues. Whereas *Suv39h1* displays broad expression in a panel of RNA preparations comprising 14 adult tissues, the expression of *Suv39h2* remains largely restricted to the testes, with mRNAs being present as 2.7- and 1.7-kb transcripts (Fig. 5A, middle panel). In addition to other tissues, *Suv39h2* transcripts are also significantly downregulated in ovaries.




FIG. 5. Testis specific expression of *Suv39h2*. (A) RNA blot analysis to detect *Suv39h1* and *Suv39h2* transcripts in 15  $\mu$ g of total RNA prepared from adult 129/Sv tissues, including kidney (KI), skeletal muscle (SM), heart (HA), liver (LI), stomach (ST), intestine (IN), lung (LU), brain (BR), spleen (SP), thymus (TH), testis (TE), ovaries (OV), uterus (UT), and placenta (PL). As a loading control, the RNA blot was rehybridized with a probe that is specific for *Gapdh* sequences. (B) RNA in situ hybridizations on 5- $\mu$ m sections of adult testis with *Suv39h1*- and *Suv39h2*-specific riboprobes. As a control, sections were also hybridized with the corresponding *Suv39h1*- and *Suv39h2*-specific sense probes. Enlarged insets show specific staining of type B spermatogonia and preleptotene spermatocytes (indicated by arrows).

Vol. 20, 2000


TESTIS-SPECIFIC EXPRESSION OF *Suv39h2* 9429

FIG. 6. Detection and size of endogenous Suv39h2 protein. Approximately 30  $\mu$ g of nuclear extracts from HeLa-B55, HeLa-S2/5, PMEFs, and adult testis (TE) were immunoblotted with  $\alpha$ -myc,  $\alpha$ -Suv39h1,  $\alpha$ -Suv39h2, and  $\alpha$ -M31 (as a loading control) antibodies. HeLa-B55 cells overexpress (myc)<sub>3</sub>-SUV1(3–412), and HeLa-S2/5 cells overexpress (myc)<sub>3</sub>-Suv2(83–477). Ectopic proteins are indicated by arrowheads. Endogenous Suv39h2 (53 kDa) almost comigrates with (myc)<sub>3</sub>-Suv2(83–477).

To analyze this testis-specific expression in more detail, we performed *in situ* hybridizations on sagittal sections of adult testes. The *Suv39h2* and *Suv39h1* antisense probes revealed specific expression in the outermost cell layer of the seminiferous tubules (Fig. 5B, right panels), whereas the corresponding control sense probes proved negative. *Suv39h2*-specific transcripts appear at elevated levels compared to *Suv39h1*. Higher magnification (see insets in Fig. 5B) shows predominant staining of type B spermatogonia and preleptotene spermatocytes. *Suv39h2*-specific transcripts are also detected at reduced levels in several pachytene-stage cells and in mitotically inactive Sertoli cells (data not shown). Together, these data indicate prominent expression of *Suv39h2* transcripts in male germ cells during the early stages of spermatogenesis.

**Detection and size of the endogenous Suv39h2 protein.** To characterize the Suv39h2 protein at a biochemical level, we generated a Suv39h2-specific polyclonal rabbit antiserum (see Materials and Methods) and probed protein blots containing nuclear extracts from PMEFs and from adult testes with affinity-purified  $\alpha$ -Suv39h2 antibodies. As a specificity and size control, we included nuclear extracts from HeLa cell lines that “stably” overexpress (myc)<sub>3</sub>-SUV39H1 (HeLa-B55) (30) or a corresponding (myc)<sub>3</sub>-Suv39h2 construct which encodes amino acids 83 to 477 of the Suv39h2 cDNA (HeLa-S2/5) (see Materials and Methods). Immunoblotting with  $\alpha$ -Suv39h1 antibodies indicated the presence of ectopic (myc)<sub>3</sub>-SUV39H1 (55 kDa) and of endogenous SUV39H1 (48 kDa) in HeLa-B55 nuclear extracts. However, endogenous Suv39h1 was undetectable in PMEFs and detectable only at low-abundant levels in testes (Fig. 6, middle panel). By contrast, the  $\alpha$ -Suv39h2 antibodies recognize an endogenous protein of ~53 kDa in both PMEFs and testes (Fig. 6, lower panel), which comigrates with ectopic (myc)<sub>3</sub>-Suv2(83–477) in HeLa-S2/5 nuclear extracts.




FIG. 7. Recombinant Suv39h2 is an H3 Lys9-selective HMTase. (A) *In vitro* HMTase assays with 10  $\mu$ g of GST-Suv2(157–477) (murine Suv39h2) and free histones, using S-adenosyl-[methyl-<sup>14</sup>C]-L-methionine as a methyl donor. Coomassie blue staining (top panel) shows purified proteins (arrowhead) and free histones (dots). Fluorography (bottom panel) indicates H3 HMTase activity of GST-Suv2(157–477). (B) *In vitro* methylation assays using GST-Suv2(157–477) as enzyme and the indicated N-terminal peptides of H3, CENP-A, and methyl-H2A as substrates.

We conclude that Suv39h2 is more highly expressed in PMEFs and in testes than is Suv39h1 and that the size of the endogenous Suv39h2 protein is in good agreement with the gene product predicted from the coding sequence of the *Suv39h2* cDNA (see Fig. 1).

**Suv39h2 is a second H3 Lys9 HMTase.** SU(VAR)3-9 related proteins were recently shown to be novel histone H3 methyltransferases. Although Suv39h1 selectively methylates Lys9 of the histone H3 N terminus, a weak signal was also detected if histone H1 was used as a substrate (36). To compare the HMTase specificity of Suv39h2, we performed *in vitro* methylation assays with free histones and a recombinant GST-Suv39h2 product that comprises amino acids 157 to 477. Purified GST-Suv2(157–477) only methylated histone H3, but not




FIG. 8. In situ localization of Suv39h2 and M31 (HP1 $\beta$ ) in testis sections. Double-labeling indirect immunofluorescence for Suv39h2 (pink) and Sep3 (green) (A and C) or for M31 (pink) and Sep3 (green) (B and D) in testis sections representing different stages of spermatogenesis. DNA was counterstained with DAPI. The positions of early and late spermatocytes (eSP and lSP), round spermatids (rST), and elongating spermatids (eST) are shown. Staining of the XY body in lSP is indicated by arrowheads. Also highlighted by arrows in panel D is the concentration of M31 around clustered centromeres in the nuclear periphery of lSP and rST.

H2A, H2B, or H4 (Fig. 7A). Notably, histone H1 was also not a substrate. To investigate the methylation site profile of Suv39h2, we extended the *in vitro* methylation assays with unmodified, modified, or mutated H3 N-terminal peptides. Whereas the unmodified H3 peptide was strongly methylated, mutation of Lys9 (K9I) abolished substrate specificity (Fig. 7B). Further, preexisting acetylation of Lys9 (K9-Ac) or phosphorylation of serine 10 (S10-phos) prevented Suv39h2-dependent methylation, and acetylation of lysine 14 (K14-Ac), like mutation of lysine 4 (K4I), significantly reduced the H3 substrate quality. The H3 variant CENP-A has been shown to be retained in sperm chromatin (34), and macroH2A is a new component of the XY body (24). However, the Suv39h2 HMTase did not react with the CENP-A and macroH2A N-terminal peptides (Fig. 7B). Together, these data define Suv39h2 as a second H3 (Lys9) selective HMTase, whose substrate specificity and sensitivity to preexisting H3 tail modifications appears even more stringent than that of Suv39h1.

**In situ localization of Suv39h2 and M31 (HP1 $\beta$ ) in testes sections.** To analyze the distribution and nuclear localization of the Suv39h2 HMTase during spermatogenesis, we performed double-labeling immunofluorescence for Suv39h2 and Sep3 epitopes in testes sections. Sep3 is a major component of the lateral elements of the synaptonemal complex, which is formed between homologous chromosomes during meiotic prophase (22). Prominent Suv39h2 signals were visualized in late, but not early, spermatocytes in a subnuclear region that displays a characteristic DAPI staining, reminiscent of the XY body (arrowheads in Fig. 8C). This staining indicated that Suv39h2 has a preference to localize to the sex chromosomes (see below). In addition, Suv39h2 is present at DAPI-dense blocks of heterochromatin (clustered centromeres) in round spermatids but was no longer detectable in elongating spermatids (Fig. 8A and C). To evaluate this staining pattern, we repeated the immunofluorescence with  $\alpha$ -Sep3 and  $\alpha$ -M31 antibodies (49) that are specific for HP1 $\beta$ , a known interacting partner for Suv39h1 or Suv39h2 proteins in somatic cells (1). As recently described (32), HP1 $\beta$  was detected at the XY body and at clustered centromeres in the nuclear periphery of mid and late spermatocytes (arrows in Fig. 8D). Moreover, HP1 $\beta$

also decorated the heterochromatic blocks of round spermatids. Thus, this comparative analysis indicates significant overlap in meiotic chromatin association between Suv39h2 and HP1 $\beta$  in different stages of mouse spermatogenesis.

**Dynamic heterochromatin association of Suv39h2 in male germ cells.** To investigate chromosomal associations of Suv39h2 in more detail, we analyzed its distribution in structurally preserved testis suspension cells (see Materials and Methods). Endogenous Suv39h2 is found in a dispersed distribution in some premeiotic nuclei (data not shown) and as a granular stain in all preleptotene nuclei (Fig. 9A, PL). During the development of leptotene to diplotene spermatocytes (eSP to dSP), Suv39h2 staining is weakly but distinctly apparent at blocks of heterochromatin, as visualized by the bright DAPI counterstaining. Prominent Suv39h2 signals accumulate at the sex chromosomes present in the XY body during the mid to late pachytene stage (ISP, arrowhead). After the meiotic divisions, Suv39h2 remains enriched at the condensing heterochromatic foci and chromosome centers of haploid spermatids (lSTs) but is no longer detectable in mature sperm (data not shown).

To demonstrate the specific accumulation of Suv39h2 with the XY body, we performed double immunofluorescence analyses for Suv39h2 and Xmr, which selectively associates with the axes and chromatin of sex chromosomes (12). The results of these analyses show that Suv39h2 colocalizes with Xmr at the XY body in 48% of evaluated spermatocytes ( $n = 194$ ) containing a prominent Xmr staining of the sex chromosomes (Fig. 9B). Whereas immunolocalization of Suv39h2 at the XY body and at the chromosome centers of haploid spermatids can be observed by several staining techniques, the visualization of Suv39h2 at heterochromatin in developing spermatocytes requires triple labeling (see Materials and Methods). Despite these variations in the detection sensitivity, our data indicate a dynamic heterochromatin distribution for Suv39h2 during most stages of spermatogenesis. By contrast, in parallel analyses of testes swab preparations with  $\alpha$ -Suv39h1 antibodies, immunolocalization of Suv39h1 only revealed very weak labeling that did not show a preference for heterochromatin (data not shown).

Vol. 20, 2000


TESTIS-SPECIFIC EXPRESSION OF *Suv39h2* 9431

FIG. 9. Dynamic heterochromatin association of Suv39h2 in male germ cells. (A) Indirect immunofluorescence of testis suspension cells with  $\alpha$ -Suv39h2 antibodies (red). DNA was counterstained with DAPI (blue). Staging of individual mouse spermatogenic cells was determined as described in Materials and Methods and comprised preleptotene spermatogonia (PL); early, middle, and late spermatocytes (eSP, mSP, and lSP); diplotene spermatocytes (dSP); and round spermatids (rSTs). Merged images are artificially colored yellow. (B) Double-labeling indirect immunofluorescence for Suv39h2 (red) and Xmr (green) in late-pachytene spermatocytes of adult testis suspension cells. DNA was counterstained with DAPI (blue). The XY body (sex vesicle) in panel A is indicated by an arrowhead.

## DISCUSSION

Murine *Suv39h* genes are encoded by two loci. Using sequence information from isolated cDNAs, ESTs, and genomic sequences, we defined *Suv39h2* as a novel gene encoding a protein of 477 amino acids (Fig. 1). The size and authenticity of the Suv39h2 gene product has been confirmed by immunodetection of a 53-kDa endogenous protein in nuclear extracts of PMEFs and testis (see Fig. 6). RNA blot analyses (see Fig. 4A and data not shown) indicate that the most abundant *Suv39h2* transcripts are 2.7 kb, suggesting that the *Suv39h2* mRNA is composed of 1.5-kb coding and 1.2-kb 3'-untranslated sequences. In addition, smaller-sized transcripts of 1.7 kb are also present at day E10.5 of mouse embryogenesis and in adult testis. Although an alternative short exon (preceding the starting ATG by ~260 bp and encoding the amino acids MASDLRT-) can be predicted from the genomic sequence, both the 1.7- and the 2.7-kb transcripts hybridize with exon 1 sequences (data not shown). Since we failed to detect endogenous proteins distinct from the 53-kDa Suv39h2 gene product, the smaller-sized transcripts do not appear to give rise to a largely different Suv39h2 isoform.

From all available sequence information, similarity searches against EST databases and reduced stringency hybridizations (data not shown), murine Suv39h proteins appear to be encoded by no more than two gene loci. Using FISH and haplotype analysis, we mapped the *Suv39h2* locus to the subcentromeric region of mouse chromosome 2 (Fig. 2 and 3). Our localization data characterizes *Suv39h2* as one of the most proximal gene markers on mouse chromosome 2 and would predict a syntenic position for *SUV39H2* on human chromosome 10p13-p15. Within this region, loss of heterozygosity has been correlated with human gliomas (26). In contrast, *Suv39h1* resides at the tip of the X chromosome in the immediate vicinity of the mouse mutations *Td* (13) and *Sf* (39). However, the recent correlation of mutations in a gene encoding a sterol isomerase with the *Td* phenotype (16) and the absence of apparent alterations for *Suv39h1* in *Sf/Y* mice (10) would indicate that *Suv39h1* is nonallelic to *Td* or *Sf*.

**Chromatin association of Suv39h2 in somatic versus meiotic cells.** In our previous studies, we identified Suv39h1 and SUV39H1 as heterochromatic proteins that associate with centromeric positions of metaphase chromosomes (1, 2). Although Suv39h2 can be detected in some mammalian cell lines (data not shown) and in PMEFs (see Fig. 6), we failed to visualize endogenous Suv39h2 at heterochromatic foci or at mitotic chromosomes in these cells. By contrast, transient expression of (myc)-Suv2(83-477) in murine Cop8 cells results in preferred heterochromatic localizations at a low abundance of ectopic protein (data not shown). This observation suggests that the highly basic N terminus is not required for the intrinsic chromatin affinity of Suv39h2 but may modulate chromosomal associations in somatic versus meiotic chromatin. This interpretation is supported by the apparent preference of Suv39h2 for heterochromatin in pachytene spermatocytes and round spermatids (see Fig. 9), whereas Suv39h2 displays a rather broad nuclear staining in Sertoli cells (data not shown). Because SUV39H1 has been shown to be a phosphoprotein with mitosis-specific isoforms (2) which appears further regulated by the anti-phosphatase Sbf1 (18), it is likely that phosphorylation-dependent modifications could also contribute to the distinct distributions of Suv39h2 in mitotic and meiotic chromatin.

**Suv39h HMTases and histone H3 tail modifications.** Suv39h-dependent methylation of Lys9 in the histone H3 N terminus has been shown to modulate chromatin dynamics in

somatic cells, in part by interfering with the phosphorylation of adjacent serine 10 (phosH3) (36), a modification required for the condensation and segregation of chromosomes (48). Moreover, heterochromatin association of HP1 is perturbed upon forced expression of SUV39H1 in HeLa cells (30), and methylation of Lys9 in H3 generates a high-affinity binding site for HP1 proteins in native chromatin of PMFs (M. Lachner, D. O'Carroll, S. Rea, K. Mechtler, and T. Jenuwein, submitted for publication). Similarly, overexpression of (myc)<sub>3</sub>-Suv2(83–477) in HeLa cells also redistributes endogenous HP1 $\beta$  (data not shown). Suv39h2 is an H3 Lys9-selective HMTase, whose substrate specificity and sensitivity to preexisting H3 tail modifications appears to be even more stringent than that of Suv39h1 (see Fig. 7). These findings indicate that both Suv39h HMTases can transduce the H3 Lys9 methylation mark into an important epigenetic signal for the induction and assembly of mammalian heterochromatin in somatic cells.

**A role for the Suv39h2 HMTase in the male germ line?** Dynamic transitions in chromatin structure are particularly important during male meiosis (see the introduction), where heterochromatinization has been proposed to be involved in the progressive centromere clustering of chromosomes (31). Because phosH3 also defines centromeric heterochromatin in meiosis (14), Suv39h2 could modulate the timing and/or degree of H3 phosphorylation, thereby influencing chromosome alignments during the meiotic divisions. In addition to such a centromeric model, meiotic chromatin associations of the Suv39h2 HMTase extend to the spermatid stage and significantly overlap with HP1 $\beta$  (see Fig. 8), suggesting that Suv39h2-induced alterations could further contribute to the dense packaging of chromatin in elongating spermatids. HP1 $\beta$  has recently been shown to be retained in mature spermatozoa by protein blot analysis (23). Similarly, ~15% of human sperm chromatin remains complexed with histones (19). Although the presence of Suv39h2 in mature sperm is currently undefined, its highly basic N terminus could facilitate associations with condensing chromatin in elongating and elongated spermatids, when histones are replaced by protamines (6).

Most interestingly, Suv39h2 and HP1 $\beta$  (32) accumulate with the silenced sex chromosomes present in the XY body (Fig. 8 and 9). This finding is particularly intriguing, since SUV39H1 (18) and HP1 $\beta$  (33, 40) have been shown to repress gene activity in somatic cells (18). Because of the high conservation between mammalian Suv39h proteins (Fig. 1), these data imply that Suv39h2 would represent an important regulator to induce silenced chromatin domains at selective chromosomes during spermatogenesis. Based on the results presented here, we even propose that the Suv39h2 HMTase could impart an epigenetic imprint to the male germ line.

#### ACKNOWLEDGMENTS

We thank Gotthold Schaffner, Robert Kurzbauer, and Ivan Dotto for sequence analysis and oligonucleotide synthesis; Alexander Schleiffer for database searches on the *C. elegans* C15H11.5 ORF; Meinrad Husslinger for advice on the exon/intron organization of the genomic *Suv39h2* clone; Jean-Louis Guenet (Pasteur Institute, Paris, France) for his gift of WMP mice; Cécile Mignon-Ravix for help in the FISH analysis; Priya D. Singh (The Roslin Institute, Roslin, Midlothian, United Kingdom) for  $\alpha$ -M31 (HP1 $\beta$ ) antibodies; Christa Heyting (Wageningen, The Netherlands) for  $\alpha$ -Sep3 antibodies; H.-J. Garchon (Hopital Necker, Paris, France) for  $\alpha$ -Xmr antibodies; and Kurt Mechtler for Suv39h2 antiserum purification.

This work was supported by the IMP through Boehringer Ingelheim and by grants from the Austrian Research Promotion Fund to T.J., the Deutsche Forschungsgemeinschaft (grant number DFG #350/8-2) to H.S., the Medical Research Council (United Kingdom) to S.D.M.B.,

and the ARC (Association pour la Recherche sur le Cancer) to M.G.M.

#### REFERENCES

1. Asgaard, L., G. Lallier, P. Schenck, M. Schmidt, R. Dorn, G. Schotta, S. Kuhlittig, A. Wolf, A. Lebersanger, P. D. Singh, G. Reuter, and T. Jenuwein. 1999. Functional mammalian homologues of the *Drosophila* PIV modifier *Su(hw)3-9* encode centromere-associated proteins which complex with the heterochromatin component M31. *EMBO J.* 18:1923–1938.
2. Asgaard, L., M. Schmidt, P. Warburton, and T. Jenuwein. 2000. Mitotic phosphorylation of SUV39H1, a novel component of active centromeres, coincides with transient accumulation at mammalian centromeres. *J. Cell Sci.* 113:817–829.
3. Allshire, R. C., K. R. Nimmo, K. Kewell, J. P. Juvarez, and G. Gransam. 1995. Mutations derepressing silent centromeric domains in fission yeast disrupt chromosome segregation. *Genes Dev.* 9:218–233.
4. Altschul, S. F., T. L. Madden, A. A. Schaffer, J. Zhang, Z. Zhang, W. Miller, and D. J. Lipman. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res.* 25:3389–3402.
5. Ayoub, N., C. Richter, and J. Wahrman. 1997. Xmr RNA is associated with the transcriptionally inactive XY body in mammalian male meiosis. *Chromosoma* 106:1–10.
6. Ballhorn, R., S. Weston, C. Thomas, and A. J. Wyrobek. 1984. DNA packaging in mouse spermatids: synthesis of protamine variants and four transition proteins. *Exp. Cell Res.* 150:298–308.
7. Bassett, D. R., Jr., M. S. Boguski, F. Spencer, R. Reeves, M. Goehf, and P. Hietter. 1995. Comparative genomics, genome cross-referencing and XRFALT. *Trans. Genet.* 11:372–373.
8. Beren, M., I. Denkin, B. Macdonald, S. Miller, R. Sibson, F. Tartelin, et al. 1994. Towards high resolution maps of the mouse and human genomes—a facility for ordering markers to 0.1 cM resolution. *Hum. Mol. Genet.* 3:621–627.
9. Brown, S. W. 1966. Heterochromatin. *Science* 151:417–425.
10. Bullman, S., and T. Magnuson. 2000. Molecular and genetic analysis of the mouse homolog of the *Drosophila* suppressor of position-effect variegation 3-9 gene. *Mamm. Genome* 11:251–254.
11. Bunick, D., P. A. Johnson, T. R. Johnson, and N. B. Heydt. 1990. Transcription of the testis-specific mouse protamine 2 gene in a homologous *in vitro* system. *Proc. Natl. Acad. Sci. USA* 87:891–895.
12. Calenda, A. B., D. Alleuet, D. Escalier, J. F. Bach, and H.-J. Garchon. 1994. The meiosis-specific Xmr gene product is homologous to the lymphocyte Xlr protein and is a component of the XY body. *J. Mol. Biol.* 130:100–109.
13. Castanach, B. M. 1982. A new X-linked mutation. *Th. Mouse News Lett.* 66:61–62.
14. Cobb, J., M. Mlynick, A. Kikuchi, and M. A. Handel. 1999. Meiotic events at the centromeric heterochromatin: histone H3 phosphorylation, topoisomerase IIa localization and chromosome condensation. *Chromosoma* 108:412–425.
15. Dersburg, A. F., J. W. Sedat, and R. S. Hawley. 1996. Direct evidence for a role of heterochromatin in meiotic chromosome segregation. *Cell* 86:135–146.
16. Derry, J. M., E. Gormally, G. D. Meens, W. Zhao, A. Melndi, R. L. Kelley, et al. 1999. Mutations in a delta 8-delta 7 steroid isomerase in the *hmr* mouse and X-linked dominant chondrodysplasia punctata. *Nat. Genet.* 3:286–290.
17. Dugaiczky, A., J. A. Naron, E. M. Stone, O. E. Deonlan, K. N. Rothman, and R. J. Schwartz. 1983. Cloning and sequencing of a deoxyribonucleic acid copy of glyceraldehyde-3-phosphate dehydrogenase messenger ribonucleic acid isolated from chicken muscle. *Biochemistry* 22:1605–1613.
18. Firestein, R., X. Cui, P. Hale, and M. L. Cleary. 2000. SET domain-dependent regulation of transcriptional silencing and growth control by SUV39H1, a mammalian ortholog of *Drosophila* SU(VAR)3-9. *Mol. Cell. Biol.* 20:4900–4909.
19. Gasse, M., P. Santiere, D. Bélaiche, A. Marlinge, C. Roux, J.-P. Dadoine, and P. Chevallier. 1986. Purification and characterization of nuclear basic proteins of human sperm. *Biochim. Biophys. Acta* 884:124–134.
20. Geraghty, M. T., L. C. Brody, L. S. Martin, M. Marble, W. Kearns, P. Pearson, A. P. Monaco, H. Lebrach, and D. Valle. 1993. The isolation of cDNAs from OAT1.1 at Xp11.2 using a 480-kb YAC. *Genomics* 16:440–446.
21. Handel, M. A., and P. A. Hunt. 1992. Sex-chromosome pairing and activity during mammalian meiosis. *Bioessays* 12:817–822.
22. Heyting, C., R. J. Deltmire, A. J. J. Dietrich, E. J. W. Reideker, and A. C. G. Vink. 1988. Two major components of synaptonemal complexes are specific for meiotic prophase nuclei. *Chromosoma* 96:325–332.
23. Hoyer-Fender, S., P. B. Singh, and D. Motzkus. 2000. The murine heterochromatin protein M31 is associated with the chromocenter of round spermatids and is a component of mature spermatozoa. *Exp. Cell Res.* 254:72–79.
24. Hoyer-Fender, S., C. Costanzi, and J. R. Pehrson. 2000. Histone macroH2A1.2 is concentrated in the XY-body by the early pachytene stage of spermatogenesis. *Exp. Cell Res.* 258:254–264.
25. Ivanova, A. V., M. J. Bonadure, S. V. Ivanov, and A. J. S. Klar. 1998. The chromo and SET domains of the Ctr4 protein are essential for silencing in

Vol. 20, 2000

TESTIS-SPECIFIC EXPRESSION OF *Suv39h2* 9433

- fission yeast. *Nat. Genet.* 19:192-195.
26. Klumpchman, A. C., D. A. Russ, and B. C. Ljung. 1996. Loss of heterozygosity of chromosome 10p in human gliomas. *Genomics* 34:250-254.
  27. Keelowski, M., A. Novella, and R. Benavente. 1997. A novel *M*, 77,000 protein of the XY body of mammalian spermatocytes: its localisation in normal animals and in Searle's translocation carriers. *Chromosoma* 106:160-167.
  28. Laible, G., A. R. Haynes, A. Lebersorger, D. O'Carroll, M.-G. Mattel, P. Demig, S. D. M. Brown, and T. Jenewein. 1999. The murine *Polycomb*-group genes *Ezh1* and *Ezh2* map close to *Hox* gene clusters on mouse chromosomes 11 and 6. *Mamm. Genome* 10:311-314.
  29. Marahrens, Y., B. Panning, J. Dausmann, W. Strauss, and R. Juenisch. 1997. Atm deficient mice are defective in dosage compensation but not spermatogenesis. *Genes Dev.* 11:156-166.
  30. Melcher, M., M. Schmidt, I. Aagaard, P. Selenka, G. Laible, and T. Jenewein. 2000. Structure-function analysis of SUV39H1 reveals a dominant role in heterochromatin organization, chromosome segregation and mitotic progression. *Mol. Cell Biol.* 20:3728-3741.
  31. Meyer-Ferns, M., J. Müller-Navin, and H. Scherthan. 1998. Clustering of pericentromeres initiates in step 9 of spermiogenesis of the rat (*Rattus norvegicus*) and contributes to a defined genome architecture in the sperm nucleus. *J. Cell Sci.* 111:1363-1370.
  32. Motzkus, D., P. B. Stagle, and S. Hoyer-Fendler. 1999. M31, a murine homolog of *Drosophila* HPI, is concentrated in the XY body during spermatogenesis. *Cytogenet. Cell Genet.* 86:83-88.
  33. Nielsen, A. L., J. A. Ortiz, J. You, M. Oulad-Abdelghani, R. Khochimian, A. Gassmuller, P. Chambon, and R. Lowson. 1999. Interaction with members of the heterochromatin protein 1 (HPI) family and histone deacetylation are differentially involved in transcriptional silencing by members of the TIF1 family. *EMBO J.* 18:6385-6395.
  34. Palmer, D. K., K. O'Day, and R. L. Margolis. 1990. The centromere specific histone CCNP-A is selectively retained in discrete foci in mammalian sperm nuclei. *Chromosoma* 100:32-36.
  35. Pandita, T. K., C. H. Westphal, M. Anger, S. G. Sawant, C. R. Géard, R. K. Pandita, and H. Scherthan. 1999. Atm inactivation results in aberrant telomere clustering during meiotic prophase. *Mol. Cell Biol.* 19:5096-5105.
  36. Ren, S., F. Eisenhaber, D. O'Carroll, B. D. Strahl, Z.-W. Sun, M. Schmid, S. Opravil, K. Melcher, C. P. Panning, C. D. Allis, and T. Jenewein. 2000. Regulation of chromatin structure by site-specific histone H3 methyltransferases. *Nature* 406:593-599.
  37. Reuter, G., and P. Spierer. 1992. Position-effect variegation and chromatin proteins. *Bioessays* 14:605-612.
  38. Rhoder, M., R. Straw, S. Fernandez, A. Evans, T. Lacey, A. Dearlove, et al. 1998. A high resolution intersatellite map of the mouse genome. *Genome Res.* 8:531-542.
  39. Russell, W. J., L. B. Russell, and J. S. Gower. 1959. Exceptional inheritance of a sex linked gene in the mouse explained on the basis that the X/O sex-chromosome constitution is female. *Proc. Natl. Acad. Sci. USA* 45:554-560.
  40. Ryan, F. R., D. C. Schultz, K. Ayyanathan, P. B. Singh, J. R. Friedman, W. J. Fredericks, and F. J. Rauscher III. 1999. KAP-1 corepressor protein interacts and colocalizes with heterochromatic and euchromatic HPI proteins: a potential role for Krüppel-associated box-zinc finger proteins in heterochromatin-mediated gene silencing. *Mol. Cell Biol.* 19:4366-4378.
  41. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Press, Cold Spring Harbor, N.Y.
  42. Scherthan, H., S. Welch, H. Schwegler, M. Härtle, C. Heyting, and T. Cramer. 1996. Centromere and telomere movements during early meiotic prophase of mouse and man are associated with the onset of chromosome pairing. *J. Cell Biol.* 134:1109-1125.
  43. Smith, A., and R. Benavente. 1995. An *M*, 51,000 protein of mammalian spermatogenic cells that is common to the whole XY body and centromeric heterochromatin of autosomes. *Chromosoma* 103:591-596.
  44. Solari, A. J. 1974. The behaviour of the XY pair in mammals. *Int. Rev. Cytol.* 38:273-317.
  45. Strahl, B. D., and C. D. Allis. 2000. The language of covalent histone modifications. *Nature* 403:41-45.
  46. Tschiersch, B., A. Hofmann, V. Krauss, R. Dorn, G. Korge, and G. Reuter. 1994. The protein encoded by the *Drosophila* position-effect variegation suppressor gene *Su(var)3-9* combines domains of antagonistic regulators of homeotic gene complexes. *EMBO J.* 13:3822-3831.
  47. Wollrath, T. L. 1998. Unfolding the mysteries of heterochromatin. *Curr. Opin. Genet. Dev.* 8:147-153.
  48. Wei, Y., Y. Tautan, J. Brown, M. A. Gorovsky, and C. D. Allis. 1999. Phosphorylation of histone H3 is required for proper chromosome condensation and segregation. *Cell* 97:99-109.
  49. Wreggell, K. A., F. Hill, P. S. James, G. W. Hutchings, and P. B. Singh. 1994. A mammalian homolog of *Drosophila* heterochromatin protein 1 (HPI) is a component of constitutive heterochromatin. *Cytogenet. Cell Genet.* 66:99-103.



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**